Abbott reports fourth-quarter sales that miss analysts’ estimates.

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

ABT's Q4 earnings meet estimates but revenues miss, sending shares down as strong device growth is offset by weaker nutrition ...

Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 8.3% in the afternoon session after the company reported fourth-quarter revenue that missed Wall Street's ...

Abbott stock fell more than 7% in premarket trading after the company missed on Q4 revenue and gave a weaker Q1 2026 outlook, ...

Abbott Laboratories stock has reached a 52-week low, closing at $107.27. This marks a notable point for the healthcare company, as it navigates a challenging market environment. Over the past year, ...

European shares were higher today. The eurozone's STOXX 600 gained 1.09%, while Spain's IBEX 35 Index rose 1.01%. London's FTSE 100 rose 0.26%, Germany's DAX gained 1.19% and France's CAC 40 gained ...

Abbott’s stock has fallen by over 7% despite reporting strong fiscal year 2025 (FY25) revenues of $44.32bn, representing a ...

This was the stock's fourth consecutive day of losses.

Abbott's revenue has been flat over 15 months with steady Q3 EPS of $1.30, 7% growth, and upcoming Q4 international segment ...

The medical device maker announced it anticipates first quarter adjusted profits per share between $1.12 and $1.18, trailing ...